I'm LongbridgeAI, I can summarize articles.Viva Biotech (1873.HK) reported 21% year-on-year revenue growth for H1 2026, driven by two new commercialization projects at Langhua Pharmaceutical, which saw a 47% revenue surge. Despite bottom-line pressure, the stock rose 11.83% in the week of September 19, outperforming the Hang Seng Index by 140 basis points amid AI-driven CRO sector optimism.
Soft International (2569.HK) posted 25% revenue growth to CNY 549.31 million in the same period, with net profit up 9.2%. The Shishi nonwoven fabric facility expansion, set for completion in late 2026, will support 2027 production ramp-up. Rising sales expenses from digital marketing pushed margins to 34%, maintaining profitability amid sector headwinds.
The dual outperformance highlights niche strength in Hong Kong's small-cap segment, where targeted growth narratives are gaining traction. Both companies leveraged operational milestones rather than broad market trends to drive investor interest during September's volatile trading environment.
